A bio-nanocapsule containing envelope protein domain III of Japanese encephalitis virus protects mice against lethal Japanese encephalitis virus infection. 2013

Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
Molecular Microbiology Group, Department of Tropical Infectious Diseases, COMB, Tropical Biosphere Research Center, Japan.

An engineered bio-nanocapsule (BNC) comprising modified hepatitis B surface antigen L protein was used as a physical scaffold for envelope protein domain III (D3) of Japanese encephalitis virus (JEV). At the N terminus, the BNC contained a two-tandem repeat of the Z domain (ZZ) derived from Staphylococcus aureus protein A (ZZ-BNC). The Lys-rich ZZ moiety exposed on the surface of ZZ-BNC was used for chemical conjugation with the JEV D3 antigen, which had been expressed and purified from Escherichia coli. Immunization of mice with D3 loaded on the surface of ZZ-BNC (ZZ-BNC:D3) augmented serum IgG response against JEV and increased protection against lethal JEV infection. The present study suggests that innocuous recombinant antigens, when loaded on the surface of ZZ-BNC, can be transformed to immunogenic antigens.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004664 Encephalitis Virus, Japanese A species of FLAVIVIRUS, one of the Japanese encephalitis virus group (ENCEPHALITIS VIRUSES, JAPANESE), which is the etiological agent of Japanese encephalitis found in Asia, southeast Asia, and the Indian subcontinent. Japanese B Encephalitis Virus,Japanese Encephalitis Virus,Virus, Japanese Encephalitis
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
April 2014, Antiviral research,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
January 2008, Vaccine,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
January 2006, Microbes and infection,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
October 2009, Sheng wu gong cheng xue bao = Chinese journal of biotechnology,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
September 2023, Cell reports,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
August 2011, Immunology letters,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
January 2022, Vaccines,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
November 2006, The Journal of infectious diseases,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
June 2017, Virusdisease,
Takeshi Miyata, and Senji Tafuku, and Tetsuya Harakuni, and Masayuki Tadano, and Nobuo Yoshimoto, and Masumi Iijima, and Hidenori Matsuo, and Goro Matsuzaki, and Shun'ichi Kuroda, and Takeshi Arakawa
January 2009, Protein and peptide letters,
Copied contents to your clipboard!